Targets › RHCE
1 program from 1 company in 1 trial: 1 Phase 1; Hematology; next expected readout Apr 2029.
Component of the ankyrin-1 complex, a multiprotein complex involved in the stability and shape of the erythrocyte membrane. Mediates the primary membrane attachment site for ANK1 when associated with RHAG. May participate in the ammonium and carbon dioxide transport through the heterotrimer form (Probable). (UniProt, P18577)
Open in Phaseline: the race on RHCE, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Children's Hospital of Philadelphia | RH genotype matched RBC transfusions Transfusion of red blood cells matched at RHD and RHCE loci to reduce alloimmunization | RHD, RHCE | Phase 1 | Sickle Cells Disease | Apr 2029 |
Sickle Cells Disease (1)
other (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.